Pharma’s supply chain prepares for the ‘next normal’ in a post-COVID-19 world15 Jun 2020
Supply chain executives request greater visibility and transparency, especially at the supplier and manufacturer level.
By now, it is evident that the current coronavirus pandemic will affect all of pharma. Patients, employees, partners and businesses will continue to feel its effects for a long while yet. The coming weeks and months will be recognized as the transition from a world 'before' and 'after' COVID-19.
The virus and its fallout will continue to test the pharmaceutical supply chain at every point. From supplier to dispenser, COVID-19 has challenged the industry business models, outpaced its best forecasts, and elicited new and unexpected behaviors in the market.
As markets continue to respond to the crisis, companies and consumers are working hard to make sense of a rapidly changing and uncertain situation and to understand the steps needed to adapt to this 'next normal'.
With a network approaching 300,000 members, TraceLink has unique insight into the global digital supply chain. Since the crisis began, the company has been maintaining an ongoing dialogue with prominent users across the healthcare supply chain, many positioned along the frontlines of the pandemic fight.
"It has been impressive to see that all along the supply chain, the front-line companies we spoke to all have a solid grasp of the situation, implementing a rapid, real-time re-prioritization and mobilization of resources and critical staff," said Shabbir Dahod, CEO, TraceLink.
The challenges presented by COVID-19 to the industry are significant; the majority of its workforce remains remote, information technologies and networks are being pushed to their limits, reliable sources are going offline, critical ingredients are in short supply, 3-month inventories are turning into shortages and shipments are being diverted, postponed or canceled.
"Our customers are quickly transitioning from formulating a theoretical response to a disrupted supply chain to delivering a practical response. The immediate transparency provided by their early transition to a patient-driven digital supply chain is helping our network members and their supply chain partners to cope," continued Dahod.
COVID-19 will define the industry's 'next normal'. The pandemic has revealed critical gaps in how vital information about suppliers, medicines, and equipment is captured and communicated. Supply chain executives point to the need for greater visibility and transparency, especially at the supplier and manufacturer level. They also call for more real-time data to make faster, more accurate decisions, which will then enable them to respond quickly to face the unknown and unexpected.
As the pandemic progresses, and the industry experiences increasing ingredient and product shortages, several companies have needed to find alternative sources, transportation routes, and distribution solutions quickly. The 'next normal', therefore, will likely involve companies testing new scenarios that balance business sustainability and growth with crisis management to mitigate unexpected and significant supply disruptions.
During this pandemic, the industry is seeing the first major test of a supply chain in transition; many companies are now digitalizing their supply chain operations. According to Dahod, supply chain agility, visibility and transparency are now among the highest priorities for pharmaceutical companies and their healthcare customers.
All of healthcare, including patients, are extremely concerned about disruptions to the upstream supply chain and any eventual impact on critical supplies and equipment.
"We can’t lose sight of our shared responsibility for securing the global supply chain," said Dahod. He explained that several TraceLink customers have experienced difficulty in maintaining their regulatory processes under pressure. "Whatever the situation or disruption, patient safety should never be sacrificed; the industry must work together to ensure critical medicines are available where and when they are needed."
According to Dahod, as the industry transitions from a pre, to a post-COVID-19 world, the need to re-assess supply chain models and accelerate digital supply chain initiatives has never been clearer.
SGS joins with Biophytis to launch international trial of COVID-19 related respiratory failure treatment
7 Jul 2020
The CRO will undertake this clinical trial at multiple sites worldwide, starting at the AZ Sint Maarten hospital in Mechelen, Belgium.Read more
Regeneron wins $450 million US government manufacturing agreement for anti-viral antibody cocktail
7 Jul 2020
The company began scaling up manufacturing of REGN-COV2 at business risk earlier this year to ensure the immediate availability of the product if clinical trials prove successful.Read more
Croda bolsters position in life sciences with the acquisition of Avanti Polar Lipids
6 Jul 2020
The transaction will more than double Croda’s R&D capability in drug delivery.Read more
Rentschler Biopharma and Vetter team up to simplify processes
6 Jul 2020
Companies agree that the key to tackling drug development complexity is collaboration.Read more
Cambrex increases flexible manufacturing capacity at Karlskoga, Sweden facility
6 Jul 2020
An investment of $3.6 million will cover the installation of a new production line to keep pace with continued growth in commercial-scale API manufacturing.Read more
iNova Pharmaceuticals announces the launch of iPitch 2020
3 Jul 2020
Following on from the success of the inaugural iPitch launch in 2019, iNova Pharmaceuticals is delighted to announce the launch of a new round of iPitch challenges for 2020.Read more
Ajinomoto introduces fast track platform for drug product manufacturing
30 Jun 2020
AJILITY is designed to speed novel or existing therapeutics from development to manufacturing and into the clinic.Read more
CPhI Worldwide to transform into Festival of Pharma digital experience
30 Jun 2020
The 10-day event will feature an interactive digital marketplace for sourcing products and services, enhanced matchmaking for connecting with new and existing partners, and world-renowned speakers.Read more
Catalent expands beauty and plant-based consumer health softgel capabilities
30 Jun 2020
Two company sites - one in Canada, the other in Brazil - receive new softgel encapsulation lines to service local customer demand.Read more
Stevanato Group pledges to provide glass vials for potential COVID-19 vaccines
29 Jun 2020
The company agrees to provide CEPI with 100 million glass vials, which can store 20 doses per vial (2 billion doses in total).Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation